Comparative bone uptake study of alendronate sodium from vaginal suppositories prepared with polyethylene glycol and massa estarinum bases

Abstract

Keywords

• Alendronate sodium, bone uptake, vaginal suppository, massa estarinum, polyethylene glycol

Derya İlem-Özdemir1, Kamil Köseoğlu2, Makbule Aşıkoğlu1, Hayal Özkılıç2, Tamer Güneri3

Abstract

References

1. Bartl R, Frisch B, Von Tresckow E, Bartl C. Bisphosphonates in Medical Practice. Spriger-Verlag, Heidelberg, Germany. 2007, pp: 35-70.
2. Rolf W, Sparidans, Jan den H. Chromatographic analysis of bisphosphonates. Pharm World Sci 1999; 21: 1-21.
3. Chaiamnuay S, Saag KG. Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates? Rev Endocr Metab Disord 2006; 7: 101–12.
4. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30-4.
5. Ayranov M, Strezov A, Jordanova E, Piperkova E, Sergieva S. Quality control and clinical application of two bone imaging 99mTc radiopharmaceuticals. J Radio Nucl Chem 1999; 240: 349-52
6. Sambrook PN, Rodriguez JP, Wasnich RD, Luckey MM, Kaur A, Meng L, Lombardi A. Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporos Int 2004; 15: 483-8.
7. Biswas P, Wilton L, Shakir S. Pharmacovigilance study of alendronate in England. Osteoporos Int 2003; 14: 507-14.
8. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999; 36: 315-28.

9. Gertz BJ, Holland, SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58: 288-98.
10. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000; 42: 175-95.
11. Lin JH, Chen IW, deLuna FA, Hichens M. Role of calcium in plasma protein binding and renal handling of alendronate in hypo and hypercalcemic rats. J Pharmacol Exp Ther 1993; 267: 670-5.
12. Lin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate in rats. Drug Metab Dispos 1992; 20: 473-8.
13. Rossini M, Braga V, Gatti D, Gerardi D, Zamberlan N, Adami S. Intramuscularclodronate therapy in postmenopausal osteoporosis. Bone 1999; 24: 125-9.
14. Asikoğlu M, Ozguney I, Ozcan I, Orumlu O, Guneri T, Koseoğlu K, Ozkilic H. The absorption of (99m)Tcalendronate given by rectal route in rabbits. Pharm Dev Technol 2008; 13: 213-20.
15. Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev 2005; 57: 1692-712.
16. Arici M, Güneri T, Ertan G. Preparation and diffusional evaluation of sustained-release suppositories containing ibuprofen microspheres. FABAD J Pharm Sci 2004; 29: 177Özgüney (Sarigüllü) I, Özcan I, Ertan G, Güneri T. The Preparation and Evaluation of Sustained Release Suppositories Containing Ketoprofen and Eudragit RL 100 by Using Factorial Design. Pharm Dev Technol 2007; 12: 97Thawatchai P, Parichart C, Tharatree S, Chirayu S. Role of Xanthan Gum on Propranolol HCl Release from Single and Double Layered Suppositories. RJPBCS 2013; 4: 1034Henry C. The Advantages of Using Suppositories, Nursing Times 1999; 95: 50-41
17. Kellaway IW, Marriott C. Correlations between physical and drug release characteristics of polyethylene glycol suppositories. J Pharm Sci 1975; 64: 1162-6
18. Gjellan K, Graffner C, Quiding H. İnfluence of Amount of Hard Fat in Suppositories on The İn Vitro Release Rate and Bioavailability of Paracetamol and Codeine. Int J Pharm 1994; 102: 71-80
19. Krishnaiah YS, Satyanarayana S, Rama Prasad YV, Narasimha Rao S. Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers. J Control Release 1998; 13; 55: 245-52. Marvola T, Marvola J, Kanerva H, Ahonen A, Lindevall K, Marvola M. Neutron activation based gamma scintigraphic evaluation of enteric-coated capsules forlocal treatment in colon. Int J Pharm. 2008; 2; 349: 24-9.